Bluesky Facebook Reddit Email

Pentraxin 3 as a noninvasive biomarker of fibrosis and carotid intima-media thickness in patients with metabolic associated fatty liver disease

06.25.24 | Xia & He Publishing Inc.

SAMSUNG T9 Portable SSD 2TB

SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.

Metabolic-associated fatty liver disease (MAFLD) may increase the risk of cardiovascular events. In this study, we assessed the predictive value of pentraxin 3 (PTX3) for severe fibrosis and carotid intima-media thickness (CIMT) in patients with MAFLD.

188 patients (114 with MAFLD, 74 with dual etiology MAFLD and chronic hepatitis C) were included. All participants underwent clinical history and examination, metabolic parameter assessment, serum level evaluation of PTX3, Fibrosis-4 index and nafld fibrosis score scores, abdominal ultrasound, and CIMT assessment.

The serum PTX3 was significantly elevated in patients with advanced fibrosis compared to those with mild/moderate fibrosis (1.8 vs 1.4, p = 0.006). The PTX3 level was independently associated with advanced fibrosis (odds ratio = 1.26, 95% confidence interval 1.008–1.040). In MAFLD patients, the PTX3 levels in patients with low fibrosis compared to those with advanced fibrosis were 1.4 (1–2.1) and 1.9 (1.3–3.8), respectively (p = 0.027). A significantly greater CIMT was noted in patients with elevated PTX3 levels (3.85 (3.42–4) vs 4.05 (3.7–4.67), p = 0.0001) compared to those with low PTX3 levels.

In this study, we demonstrated that PTX3 accurately predicts the presence of advanced fibrosis and CIMT in a population with MAFLD. Thus, it could be useful for risk stratification and management. Further independent studies will be required to confirm these findings in larger cohorts and in the general population, which has diverse representations of individuals of other races and ethnicities.

https://www.xiahepublishing.com/1555-3884/GE-2023-00047

The study was recently published in the Gene Expression .

Gene Expression (GE) is an open-access journal. It was launched in 1991 by Chicago Medical School Press, and transferred to Cognizant Communication Corporation in 1994. From August 2022, GE is published by Xia & He Publishing Inc.

GE publishes peer-reviewed and high-quality original articles, reviews, editorials, commentaries, and opinions on its primary research topics including cell biology, molecular biology, genes, and genetics, especially on the cellular and molecular mechanisms of human diseases.

GE has been indexed in Medline (1991-2021), Scopus, Biological Abstracts, Biosis Previews, ProQuest, etc .

Follow us on X: @xiahepublishing

Follow us on LinkedIn: Xia & He Publishing Inc.

Gene Expression

10.14218/GE.2023.00047

Pentraxin 3 as a Noninvasive Biomarker of Fibrosis and Carotid Intima-media Thickness in Patients with Metabolic Associated Fatty Liver Disease

29-May-2024

Keywords

Article Information

Contact Information

Shelly Zhang
Xia & He Publishing Inc.
service@xiahepublishing.com

Source

How to Cite This Article

APA:
Xia & He Publishing Inc.. (2024, June 25). Pentraxin 3 as a noninvasive biomarker of fibrosis and carotid intima-media thickness in patients with metabolic associated fatty liver disease. Brightsurf News. https://www.brightsurf.com/news/86ZE3098/pentraxin-3-as-a-noninvasive-biomarker-of-fibrosis-and-carotid-intima-media-thickness-in-patients-with-metabolic-associated-fatty-liver-disease.html
MLA:
"Pentraxin 3 as a noninvasive biomarker of fibrosis and carotid intima-media thickness in patients with metabolic associated fatty liver disease." Brightsurf News, Jun. 25 2024, https://www.brightsurf.com/news/86ZE3098/pentraxin-3-as-a-noninvasive-biomarker-of-fibrosis-and-carotid-intima-media-thickness-in-patients-with-metabolic-associated-fatty-liver-disease.html.